Genomic profiling emerges as a promising avenue for discerning HP disease, as evidenced by a case report study implicating EGFR alteration and MDM2 amplification as potential indicators for HPD in NSCLC) (90, 91). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.